RESENE AUTOMOTIVE & LIGHT INDUSTRIAL

Version No: **1.2** Safety Data Sheet according to HSNO Regulations Chemwatch Hazard Alert Code: 2

Issue Date: 08/04/2015 Print Date: 08/04/2015 Initial Date: 08/04/2015 S.GHS.NZL.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	RALI GP HARDENER
Synonyms	Not Available
Proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses 9514

Details of the manufacturer/importer

Registered company name	RESENE AUTOMOTIVE & LIGHT INDUSTRIAL
Address	32-50 Vogel Street Naenae Wellington New Zealand
Telephone	+64 4 5770500
Fax	+64 4 5773327
Website	www.resene.co.nz
Email	advice@resene.co.nz

Emergency telephone number

Association / Organisation	NZ POISONS (24hr 7 days)
Emergency telephone numbers	0800 764766
Other emergency telephone numbers	0800 737636

CHEMWATCH EMERGENCY RESPONSE

Primary Number	Alternative Number 1	Alternative Number 2
+800 2436 2255	+612 9186 1132	Not Available

Once connected and if the message is not in your prefered language then please dial 01

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

SIGNAL WORD

DANGER

Considered a Hazardous Substance according to the criteria of the New Zealand Hazardous Substances New Organisms legislation. Classified as Dangerous Goods for transport purposes.

GHS Classification ^[1]	Acute Toxicity (Inhalation) Category 5, Carcinogen Category 2, Chronic Aquatic Hazard Category 4, Eye Irritation Category 2A, Flammable Liquid Category 3, Reproductive Toxicity Category 2, Respiratory Sensitizer Category 1, Skin Corrosion/Irritation Category 2, Skin Sensitizer Category 1, STOT - SE Category 2	
Legend:	1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ ; 3. Classification drawn from EC Directive 1272/2008 - Annex VI	
Determined by Chemwatch using GHS/HSNO criteria	6.5B (contact), 6.7B, 6.4A, 6.9B, 6.1E (inhalation), 6.3A, 9.1D, 6.8B, 3.1C, 6.5A (respiratory)	
Label elements		
GHS label elements		

Hazard statement(s)

H226	Flammable liquid and vapour
H315	Causes skin irritation
H317	May cause an allergic skin reaction
H319	Causes serious eye irritation
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H351	Suspected of causing cancer
H361	Suspected of damaging fertility or the unborn child
H371	May cause damage to organs
H413	May cause long lasting harmful effects to aquatic life

Precautionary statement(s) Prevention

P201 Obtain special instructions before use.

Precautionary statement(s)) Response	
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.		
Precautionary statement(s)) Storage	
P403+P235	5 Store in a well-ventilated place. Keep cool.	
Precautionary statement(s) Disposal		
P501	Dispose of contents/container to authorised chemical landfill or if organic to high temperature incineration	

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
108-88-3	20-40	toluene
28182-81-2	20-40	hexamethylene diisocyanate polymer
822-06-0	<1	hexamethylene diisocyanate
1330-20-7	5-10	<u>xylene</u>
100-41-4	1-5	ethylbenzene

SECTION 4 FIRST AID MEASURES

NZ Poisons Centre 0800 POISON (0800 764 766) | NZ Emergency Services: 111

Description of first aid measures

Eye Contact	 If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. 			
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation. 			
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CP necessary. Transport to hospital, or doctor. Following uptake by inhalation, move person to an area free from risk of further exposure. Oxygen or artificial respiration should be administered as needed. Asthmatic-type symptoms may develop and may be immediate or delayed up to several hours. Treatment is essentially symptomatic. A physician should be consulted. 			
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice. Avoid giving milk or oils. Avoid giving alcohol. If spontaneous vomiting appears imminent or occurs, hold patient's head down, lower than their hips to help avoid possible aspiration of vomitus. 			

Indication of any immediate medical attention and special treatment needed

Any material aspirated during vomiting may produce lung injury. Therefore emesis should not be induced mechanically or pharmacologically. Mechanical means should be used if it is considered necessary to evacuate the stomach contents; these include gastric lavage after endotracheal intubation. If spontaneous vomiting has occurred after ingestion, the patient should be monitored for difficult breathing, as adverse effects of aspiration into the lungs may be delayed up to 48 hours. for simple esters:

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 l/min.
 Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for purnonal
 Monitor and treat, where necessary, for shock.
- DO NOT use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

Give activated charcoal.

ADVANCED TREATMENT

- Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.
- -----

EMERGENCY DEPARTMENT

- -----
- Laboratory analysis of complete blood count, serum electrolytes, BUN, creatinine, glucose, urinalysis, baseline for serum aminotransferases (ALT and AST), calcium, phosphorus and magnesium, may assist in establishing a treatment regime. Other useful analyses include anion and osmolar gaps, arterial blood gases (ABGs), chest radiographs and electrocardiograph.
 Positive end-expiratory pressure (PEEP)-assisted ventilation may be required for acute parenchymal injury or adult respiratory distress syndrome.
- Consult a toxicologist as necessary.

BRONSTEIN, A.C. and CURRANCE, P.L. EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

For sub-chronic and chronic exposures to isocyanates:

- This material may be a potent pulmonary sensitiser which causes bronchospasm even in patients without prior airway hyperreactivity.
- Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts.
- Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure.
- Pulmonary symptoms include cough, burning, substernal pain and dyspnoea.
- Some cross-sensitivity occurs between different isocyanates.
- Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line.
- Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids.
- Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion.
- Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions.
- There is no effective therapy for sensitised workers.

[Ellenhorn and Barceloux; Medical Toxicology]

NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992]

Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who develops chronic respiratory distress when working with isocyanates should be removed from exposure and examined by a physician. Further exposure must be avoided if a sensitivity to isocyanates or polyisocyanates has developed.

Following acute or short term repeated exposures to toluene:

- Toluene is absorbed across the alveolar barrier, the blood/air mixture being 11.2/15.6 (at 37 degrees C.) The concentration of toluene, in expired breath, is of the order of 18 ppm following sustained exposure to 100 ppm. The tissue/blood proportion is 1/3 except in adipose where the proportion is 8/10.
- Metabolism by microsomal mono-oxygenation, results in the production of hippuric acid. This may be detected in the urine in amounts between 0.5 and 2.5 g/24 hr which represents, on average 0.8 gm/gm of creatinine. The biological half-life of hippuric acid is in the order of 1-2 hours.
- Primary threat to life from ingestion and/or inhalation is respiratory failure.
- Patients should be quickly evaluated for signs of respiratory distress (eg cyanosis, tachypnoea, intercostal retraction, obtundation) and given oxygen. Patients with inadequate tidal volumes or poor arterial blood gases (pO2 <50 mm Hg or pCO2 > 50 mm Hg) should be intubated.
- Arrhythmias complicate some hydrocarbon ingestion and/or inhalation and electrocardiographic evidence of myocardial damage has been reported; intravenous lines and cardiac monitors should be established in obviously symptomatic patients. The lungs excrete inhaled solvents, so that hyperventilation improves clearance.
- A chest x-ray should be taken immediately after stabilisation of breathing and circulation to document aspiration and detect the presence of pneumothorax.
- Epinephrine (adrenaline) is not recommended for treatment of bronchospasm because of potential myocardial sensitisation to catecholamines. Inhaled cardioselective bronchodilators (e.g. Alupent, Salbutamol) are the preferred agents, with aminophylline a second choice.
- Lavage is indicated in patients who require decontamination; ensure use.

BIOLOGICAL EXPOSURE INDEX - BEI

These represent the determinants observed in specimens collected from a healthy worker exposed at the Exposure Standard (ES or TLV):

Index	Sampling Time	Comments
0.5 mg/L	End of shift	В
1.6 g/g creatinine	End of shift	B, NS
0.05 mg/L	Prior to last shift of workweek	
(0.5 mg/L 1.6 g/g creatinine	0.5 mg/L End of shift 1.6 g/g creatinine End of shift

NS: Non-specific determinant; also observed after exposure to other material

B: Background levels occur in specimens collected from subjects NOT exposed

For acute or short term repeated exposures to xylene:

Gastro-intestinal absorption is significant with ingestions. For ingestions exceeding 1-2 ml (xylene)/kg, intubation and lavage with cuffed endotracheal tube is recommended. The use of charcoal and cathartics is equivocal.

- Pulmonary absorption is rapid with about 60-65% retained at rest.
- Primary threat to life from ingestion and/or inhalation, is respiratory failure.

- Patients should be quickly evaluated for signs of respiratory distress (e.g. cyanosis, tachypnoea, intercostal retraction, obtundation) and given oxygen. Patients with inadequate tidal volumes or poor arterial blood gases (pO2 < 50 mm Hg or pCO2 > 50 mm Hg) should be intubated.
- Arrhythmias complicate some hydrocarbon ingestion and/or inhalation and electrocardiographic evidence of myocardial injury has been reported; intravenous lines and cardiac monitors should be established in obviously symptomatic patients. The lungs excrete inhaled solvents, so that hyperventilation improves clearance.
- A chest x-ray should be taken immediately after stabilisation of breathing and circulation to document aspiration and detect the presence of pneumothorax.
- Epinephrine (adrenalin) is not recommended for treatment of bronchospasm because of potential myocardial sensitisation to catecholamines. Inhaled cardioselective bronchodilators (e.g. Alupent, Salbutamol) are the preferred agents, with aminophylline a second choice.
- BIOLOGICAL EXPOSURE INDEX BEI

These represent the determinants observed in specimens collected from a healthy worker exposed at the Exposure Standard (ES or TLV):

Determinant	Index	Sampling Time	Comments
Methylhippu-ric acids in urine	1.5 gm/gm creatinine	End of shift	
	2 mg/min	Last 4 hrs of shift	

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media		
	• Small quantities of water in contact with hot liquid may react violently with generation of a large volume of rapidly expanding hot sticky semi-solid foam.	
Special hazards arising fro	om the substrate or mixture	
Fire Incompatibility	Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result	
Advice for firefighters		
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. 	
Fire/Explosion Hazard	► Liquid and vapour are flammable.	

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Minor Spills	▶ Remove all ignition sources.
Major Spills	Liquid Isocyanates and high isocyanate vapour concentrations will penetrate seals on self contained breathing apparatus - SCBA should be used inside encapsulating suit where this exposure may occur.
	Personal Protective Equipment advice is contained in Section 8 of the MSDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

Safe handling	Containers, even those that have been emptied, may contain explosive vapours.
Other information	Store in original containers in approved flammable liquid storage area.

Conditions for safe storage, including any incompatibilities

Suitable container	Packing as supplied by manufacturer.
Storage incompatibility	 n-Butyl acetate: reacts with water on standing to form acetic acid and n-butyl alcohol reacts violently with strong oxidisers and potassium tert-butoxide is incompatible with caustics, strong acids and nitrates dissolves rubber, many plastics, resins and some coatings Toluene: reacts violently with strong oxidisers, bromine, bromine trifluoride, chlorine, hydrochloric acid/ sulfuric acid mixture, 1,3-dichloro-5,5-dimethyl-2,4-imidazolidindione, dinitrogen tetraoxide, fluorine, concentrated nitric acid, nitrogen dioxide, silver chloride, sulfur dichloride, uranium fluoride, vinyl acetate forms explosive mixtures with strong acids, strong oxidisers, silver perchlorate, tetranitromethane is incompatible with bis-toluenediazo oxide attacks some plastics, rubber and coatings may generate electrostatic charges, due to low conductivity, on flow or agitation.

PACKAGE MATERIAL INCOMPATIBILITIES

Not Available

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
New Zealand Workplace Exposure Standards (WES)	toluene	Toluene	188 mg/m3 / 50 ppm	Not Available	Not Available	Skin absorption
New Zealand Workplace Exposure Standards (WES)	hexamethylene diisocyanate polymer	Isocyanates, all, (as -NCO)	0.02 mg/m3	0.07 mg/m3	Not Available	Sensitiser; These values apply to all isocyanates, including prepolymers, present in the workplace air as vapours, mist or dust.

New Zealand Workplace Exposure Standards (WES)	hexamethylene diisocyanate	lsocyanates, all, (as -NCO)	0.02 mg/m3	0.07 mg/m3	Not Available	Sensitiser; These values apply to all isocyanates, including prepolymers, present in the workplace air as vapours, mist or dust.
New Zealand Workplace Exposure Standards (WES)	xylene	Xylene (o-, m-, p-isomers)	217 mg/m3 / 50 ppm	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	ethylbenzene	Ethyl benzene	434 mg/m3 / 100 ppm	543 mg/m3 / 125 ppm	Not Available	Not Available

EMERGENCY LIMITS

Ingredient	Material name		TEEL-1	TEEL-2	TEEL-3
toluene	Toluene		Not Available	Not Available	Not Available
hexamethylene diisocyanate polymer	Hexamethylene diisocyanate polymer		7.8 mg/m3	86 mg/m3	510 mg/m3
hexamethylene diisocyanate	Hexamethylene diisocyanate; (1,6-Diisocyanatohexane)		0.005 ppm	0.02 ppm	0.8 ppm
xylene	Xylenes		Not Available	Not Available	Not Available
ethylbenzene	Ethyl benzene		Not Available	Not Available	Not Available
Ingredient	Original IDLH	Re	evised IDLH		
toluene	2,000 ppm	50	0 ppm		
hexamethylene diisocyanate polymer	Not Available	No	ot Available		
hexamethylene diisocyanate	Not Available	No	ot Available		
xylene	1,000 ppm	90	900 ppm		
ethylbenzene	2,000 ppm	80	0 [LEL] ppm		

Exposure controls

Appropriate engineering controls are used to remove a hazard or place a barrier between the worker and the hazard.

Personal protection	
Eye and face protection	 Safety glasses with side shields.
Skin protection	See Hand protection below
Hands/feet protection	 NOTE: ► The material may produce skin sensitisation in predisposed individuals.
Body protection	See Other protection below
Other protection	All employees working with isocyanates must be informed of the hazards from exposure to the contaminant and the precautions necessary to prevent damage to their health.
Thermal hazards	Not Available

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection: RALI GP HARDENER

RALI GP HARDENER

Material	CPI
BUTYL	С
BUTYL/NEOPRENE	C
CPE	С
HYPALON	C
NAT+NEOPR+NITRILE	С
NATURAL RUBBER	С
NATURAL+NEOPRENE	C
NEOPRENE	C
NEOPRENE/NATURAL	C
NITRILE	С
NITRILE+PVC	С
PE	С
PE/EVAL/PE	C
PVA	C
PVC	С

Respiratory protection

Type A Filter of sufficient capacity.

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection

varies with Type of filter.

 Required Minimum
 Half-Face
 Full-Face
 Powered Air

Protection Factor	Respirator	Respirator	Respirator
up to 5 x ES	A-AUS / Class 1	-	A-PAPR-AUS / Class 1
up to 25 x ES	Air-line*	A-2	A-PAPR-2
up to 50 x ES	-	A-3	-
50+ x ES	-	Air-line**	-

* - Continuous-flow; ** - Continuous-flow or positive pressure demand

^ - Full-face

 $\begin{array}{l} \mbox{A(All classes)} = \mbox{Organic vapours, B AUS or B1} = \mbox{Acid gasses, B2} = \mbox{Acid gas or hydrogen cyanide(HCN), B3} = \mbox{Acid gas or hydrogen cyanide(HCN), E} = \mbox{Sulfur dioxide(SO2), G} = \mbox{Agricultural chemicals, K} = \mbox{Ammonia(NH3), Hg} = \mbox{Mercury, NO} = \mbox{Oxides of nitrogen, MB} = \mbox{Methyl bromide, AX} = \mbox{Low boiling point organic compounds(below 65 degC)} \end{array}$

PVDC/PE/PVDC	С
SARANEX-23	С
SARANEX-23 2-PLY	С
TEFLON	С
VITON	С
VITON/BUTYL	С
VITON/CHLOROBUTYL	С
VITON/NEOPRENE	С

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final

selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as

"feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise

be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Note that all of the monopropylene glycol ethers may exist in two isomeric forms, alpha or beta. Clear colourless liquid with strong solvent odour					
Physical state	Liquid	Relative density (Water = 1)	0.969			
Odour	Not Available	Partition coefficient n-octanol / water	Not Available			
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available			
pH (as supplied)	Not Available	Decomposition temperature	Not Available			
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available			
Initial boiling point and boiling range (°C)	131	Molecular weight (g/mol)	Not Available			
Flash point (°C)	26	Taste	Not Available			
Evaporation rate	Not Available	Explosive properties	Not Available			
Flammability	Flammable.	Oxidising properties	Not Available			
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available			
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	66			
Vapour pressure (kPa)	Not Available	Gas group	Not Available			
Solubility in water (g/L)	Immiscible	pH as a solution	Not Available			
Vapour density (Air = 1)	Not Available	VOC g/L	588			

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	 Unstable in the presence of incompatible materials.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may be harmful.	
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual.	
Skin Contact	The material may cause moderate inflammation of the skin either following direct contact or after a delay of some time.	
Eye	This material may produce eye irritation in some persons and produce eye damage 24 hours or more after instillation.	
Chronic	There has been concern that this material can cause cancer or mutations, but there is not enough data to make an assessment.	

Continued...

Inhalation (raj) LCS: 0. 132 mg/L4H/ ²¹ Inhalation (raj) LCS: 0. 042 mg/L4H/ ²¹ Oral (raj) LDS: 710 mg/g ¹¹ TOXICITY IRRITATION Demai (rabbi) LDS: -1700 mg/g ¹² Eye (human): 200 pm initant Inhalation (raj) LCS: 0.000 pm/sh ²¹ Eye (human): 200 pm initant Inhalation (raj) LCS: 5000 pm/sh ²¹ Eye (human): 200 pm initant Inhalation (raj) LCS: 5000 pm/sh ²¹ Eye (rabbi): 87 mg mild Oral (raj) LDS: 4300 mg/g ¹² Eye (rabbi): 87 mg mild Inhalation (raj) LCS: 5500 pm/sh ²¹ Eye (rabbi): 500 mg - SEVERE Inhalation (rau) LCS: 550 mg/L2H ²¹ Eye (rabbi): 500 mg - SEVERE Inhalation (rau) LCS: 550 mg/L2H ²¹ Eye (rabbi): 500 mg - SEVERE Inhalation (rau) LCS: 550 mg/L2H ²¹ Siki (rabbi): 15 mg/24h mild Inhalation (rau) LCS: 550 mg/L2H ²¹ Siki (rabbi): 15 mg/24h mild Inhalation (rau) LCS: 550 mg/L2H ²¹ Siki (rabbi): 50 mg - SEVERE Inhalation (rau) LCS: Sis mg/L2H ²¹ Siki (rabbi): 15 mg/24h mild Inhalation (rau) LCS: Sis mg/L2H ²¹ Siki (rabbi): 50 mg - SEVERE Inhalation (rau) LCS: Sis mg/L2H ²¹ Siki (rabbi): 15 mg/L2H mild Inhalation (rau) LCS: Sis mg/L2H ²¹ Siki (rabbi): 50 mg - SEVERE Inhalation (rau) LCS: Sis mg/L				
NA valadie NA valadie NA valadie NA valadie NA valadie Septimizerizanie Septimizerizanie Septimizerizanie Nation 160 LCED. 48 regular ¹⁰ Septimizerizanie Septimizerizanie Septimizerizanie Ora 180 LDED. 58 regular ¹⁰ Septimizerizanie Nation 160 LCED. 48 regular ¹⁰ Septimizerizanie Ora 180 LDED. 58 regular ¹⁰ Septimizerizanie Nation 160 LCED. 48 regular ¹⁰ Septimizerizanie Nation 160 LCED. 400 regular ¹⁰ Septimizerizanie Nation 1		TOXICITY	IRRITATION	
Interms Perms (rabbit DDS 1212 angle ^{III} ^{IIII} ^{III} ^{IIII} ^{IIII} ^{IIII} ^{III} ^{III} ^{IIII} ^{IIII} ^{III} ^{III} ^{III}	RALI GP HARDENER	Not Available	Not Available	
Interaction Enclose (spin		тохісіту	IRRITATION	
industry inclusion Epi (excluston variable) Epi (excluston variable) industry incluston is enginge ¹²¹ Sin (incluston variable) industry incluston intreget engin sin (incluston interpretery variable) Si		Dermal (rabbit) LD50: 12124 mg/kg ^[2]	Eye (rabbit): 2n	ng/24h - SEVERE
Indexation (and LOG: 6.9 mg/s4 ²¹ Site (rabbit) 50% (Site (mg/s2) Decine (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Site (rabbit) 50% (Site (mg/s2) Resentity lene discover (mg/s2) Sit		Inhalation (rat) LC50: >26700 ppm/1hd ^[2]	Eye (rabbit):0.8	37 mg - mild
bale (red): Q2:00 (red): L300: 636 mg/sg/2 ¹²] Site (red): Q2:00 mg - moderate beraultylee diacog (L300: 530 mg / mg / l ²¹) Site (red): Q3:00 mg - moderate beraultylee diacog (L300: 5300 mg / mg / l ²¹) Site (red): Q3:00 mg - moderate beraultylee diacog (L300: 5300 mg / mg / l ²¹) Site (red): Q3:00 mg - moderate beraultylee diacog (L300: 5300 mg / mg / l ²¹) Site (red): Q3:00 mg - moderate beraultylee diacog (L300: 5300 mg / l ²¹) Net Auklate beraultylee diacog (L300: 320 mg / l ²¹) Net Auklate beraultylee diacog (L300: 320 mg / l ²¹) Net Auklate beraultylee diacog (L300: 320 mg / l ²¹) Net Auklate beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) Site (red): Site mg / l ²¹ beraultylee diacog (L300: 320 mg / l ²¹) <th>toluene</th> <td>Inhalation (rat) LC50: 49 mg/L/4H^[2]</td> <td>Eye (rabbit):10</td> <td>0 mg/30sec - mild</td>	toluene	Inhalation (rat) LC50: 49 mg/L/4H ^[2]	Eye (rabbit):10	0 mg/30sec - mild
Image: Solution in the solution is a solution is			Skin (rabbit):20	mg/24h-moderate
beamstrijee discourse at we			Skin (rabbit):50	0 mg - moderate
initiation (ad) LCSD. 15.5 mg/L/M ^{2[4} TOXICTY IRETATION Arran (ad) LCSD. 15000 mg/mg ¹²¹ Final (ad) LCSD. 15000 mg/mg ¹²¹ Final (ad) LCSD. 1520 mg/mg ¹²¹ Final (ad) LCSD. 1550 mg/L ²⁴ Final (ad) LCSD. 1550 mg/L		ΤΟΧΙΟΙΤΥ	IRRITATION	
invalian (na) LCS2: 18.5 mg/L/fm ^{2[1} invalian (na) LCS2: 18.5 mg/L/fm ^{2[1} TOXICITY INTERCENT		Dermal (rabbit) LD50: >5000 mg/kg* ^[2]	Skin (rabbit): 50	00 mg - moderate
Image: Control LDSC > 10000 mg/mg ^{1/2} IRRITATION Image: Control Contro Control Control Control Control Control Con				-
earmethylene delico yat 1000: >7000 mg/q ¹¹ 0 Mot Available in the function of the LGS0: 0.06 mg/L4P ¹² 0 integration (ed. LGS0: 0.042 mg/L4P ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 v) 700 mg/l6 ¹² 0 integration (ed. LGS0: 0.05 mg/L4P				
demail (rdl LDS0: >7000 mg/q ^[1] Nd Available Headerin (rdl LDS0: >7000 mg/q ^[1] Oral (rdl LDS0: >7000 mg/q ^[1] Oral (rdl LDS0: >7000 mg/q ^[1] Derma (rdbbl LDS0: >7000 mg/q ^[1] Derma (rdbbl LDS0: >7000 mg/q ^[1] Headern (rdl LDS0: 2000 mg/mg ^[1] Derma (rdbbl LDS0: >1000 mg/mg ^[1] Derma (rdbbl LDS0: >1000 mg/mg ^[1] Headern (rdl LDS0: >1000 mg/mg ^[1] Derma (rdbbl LDS0: >1000 mg/mg ^[1] Derma (rdbbl LDS0: >1000 mg/mg ^[1] Derma (rdbbl LDS0: >1000 mg/mg ^[1] Headern (rdb LDS0: 500 mg/mg ^{1/2}] Derma (rdbbl MGC0: S00 mg/mg ^{1/2}] Derma (rdbbl MGC0: S00 mg/mg ^{1/2}] Headerin (rdb LDS0: S00 mg/mg ^{1/2}] Derma (rdbbl MGC0: S00 mg/mg ^{1/2}] Oral (rdb LDS0: S00 mg/mg ^{1/2}] Headerin matrox mg/mg hof maxes derma matrox mg/mg/		TOVICITY	IDDITATION	
hearenershybere discorpants i relation (rat) LCS0: 0.05 mg/L4h ^[2] beatation (rat) LCS0: 0.154 mg/L4h ^[2] i relation (rat) LCS0: 0.150 mg/kg ^[2] i RRTATION Ferritor i RRTATION			1	
hearanethylene diisograma hearanethylene diiso			NOL AVAIIADIE	
Initiation (rat) LCS0: 0.482 rg/L4f ^{2]} Image: Control (rg/L) LCS0: 710 rg/kg ^{1]} Image: Control (rg/L) LCS0: 710 rg/kg ^{1]} TOXICTY IRRITATION Derral (rg/L) LCS0: 5100 rg/kg ^{12]} Eye (rg/L) 57 rg/2 rg/minited Derral (rg/L) LCS0: 5000 rg/mg ¹²] Eye (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 5000 rg/mg ¹²] Eye (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 5000 rg/mg ¹²] Eye (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/2 rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/L rg/minited Oral (rg/L) LCS0: 55 rg/L2 rg/l Skin (rg/L) 57 rg/L rg/minited Discorection rg/l rg/l Initiation rg/minited Discorection rg/l rg/l rg/l rg/l rg/l rg/l rg/l rg/l	hexamethylene diisocyanate			
Oral (rdi) LDS: 710 mg/kg ^[1] IRRITATION Dynamic (abbi) LDS: -1700 mg/kg ^[2] Eye (human): 200 ppm inflant Inhalation (rdu LDS: 5000 ppm/kl ²] Eye (nabbi): 5 mg/24h SEVERE Oral (rdi) LDS: -5000 mg/kg ^[2] Eye (nabbi): 5 mg/24h moderate Oral (rdi) LDS: -5000 ppm/kl ²] Eye (nabbi): 500 mg mg/dh Oral (rdi) LDS: -5000 ppm/kl ²] Eye (nabbi): 500 mg mg/dh Oral (rdi) LDS: -5000 mg/kg ^[2] Eye (nabbi): 500 mg mg/dh Oral (rdi) LDS: -5000 mg/kg ^[2] IRRITATION Demma (rabbi): LDS: -ca. 1542.6 mg/kg ^[1] Eye (nabbi): 50 mg-24h moderate TOXICITY IRRITATION Demma (rabbi): LDS: -ca. 1542.6 mg/kg ^[1] Eye (nabbi): 50 mg-24h mide Inhalation (rabus): LDS: -ca. 1542.6 mg/kg ^[1] Eye (nabbi): 50 mg-24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg-24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg-24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg-24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg/24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg/24h mide Inhalation (rabus): LDS: -so mg/kg ^[2] Skin (rabbi): 15 mg/24h mide Inhalation (rabus				
TOXICITY IRRITATION initiation (rate) LDS0: 51700 mg/kg ^[2] Eye (human): 200 pm initiant initiation (rate) LDS0: 5000 pm/4lp ^[2] Eye (rabbit): 6 mg/24h SEVERE Onal (rate) LDS0: 4300 mg/kg ^[2] Eye (rabbit): 6 mg/24h SEVERE Onal (rate) LDS0: 4300 mg/kg ^[2] Eye (rabbit): 6 mg/24h SEVERE Onal (rate) LDS0: 4300 mg/kg ^[2] Eye (rabbit): 6 mg/24h moderate TOXICITY IRRITATION Dermal (rabbit) LDS0: ca. 15432.6 mg/kg ¹¹ Eye (rabbit): 600 mg-SEVERE Initiation (rate) LDS0: 53.5 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Unitiation (rate) LDS0: 53.5 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Unitiation (rate) LDS0: 53.0 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Unitiation (rate) LDS0: 53.0 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Unitiation (rate) LDS0: 53.00 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Executed from RTECS - Register of Toxic Effect of chemical Substances Note chained from rmanufacturer's mads. Unless otherwise specified data data data data data data data da			 	
bernal (rebdi) LD50: >1700 mg/kg ^[2] Eye (numar): 200 ppm initiant inhalation (rat) LC50: 5000 ppm/kgl ^[2] Eye (rabbi): 5 mg/24h SEVERE Crail (rat) LD50: 4300 mg/kgl ^[2] Eye (rabbi): 57 mg mid Skin (rabbi):500 mg/24h moderate Skin (rabbi):500 mg/24h moderate Parmal (rabbi):1050: ca: 1542.6 mg/kgl ^[1] Eye (rabbi): 500 mg · SEVERE Inhalation (rat) LD50: ca: 55 mg/Lgl ^[2] Skin (rabbi): 15 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 15 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 15 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 15 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl ^[2] Skin (rabbi): 5 mg/24h mid Inhalation (rat) LD50: 35.5 mg/Lgl [[]		Oral (rat) LD50: 710 mg/kg ^[1]		
system inhalation (rat) LCS0: 5000 ppm/41 ^[2] Eye (rabbit): 57 mg/24h; SZVERE Oral (rat) LCS0: 4300 mg/kgl ^[2] Eye (rabbit): 87 mg mid Skin (rabbit):500 mg/24h; moderate ethylionzone TOXICTTY Demail (rabbit):LDS0: ca.15432.6 mg/kg ^[1] Eye (rabbit): 500 mg - SEVERE Inhalation (mouse):LCS0: 35.5 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rat):LDS0: 3500 mg/kgd ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rat):LDS0: 3500 mg/kgd ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rat):LDS0: 3500 mg/kgd ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rat):LDS0: 3500 mg/kgd ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rati):LDS0: 3500 mg/kgd ^[2] Skin (rabbit): 15 mg/24h mid Inhalation (rati):LDS0: 3500 mg/kgd ^[2] Skin (rabbit):Sto0 mg/kgd ^[2] Interview of them Europe ECHAR Registered Substances - Acute toxichy 2.: Value obtained from manufacturer's mads. Unless otherwise specified of them Interview of the skin. The material may cause skin inflation after prolonged or repeated exposure and may produce sceles system) recorded. INSOCYNANTE Reproductive of the skin. IDISOCYNANTE Reproductive of effector in rats IDISOCYNANTE The following information refers to contact allergens as a group and may not be specific		ΤΟΧΙΟΙΤΥ	IRRITATION	
Oral (rat) LD50: 4300 mg/sgl ^[2] Eye (rabbil: 87 mg mid Sitin (rabbil: 500 mg/24h moderate Sitin (rabbil: 500 mg/24h moderate Bernal (rabbil: LD50: 2.55 mg/24l ^{2]} Sitin (rabbil: 50 mg / SEVERE Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Inhalation (mouse) LC50: 35.5 mg/24l ^{2]} Sitin (rabbil: 15 mg/24h mild Intervert The material may cause skin intration after protoged or lowelay extreme IDISOCYAMPTE POLYMER Invert Angese during the factor in rats Intervert + TYLENE Reproductive effector in rats		Dermal (rabbit) LD50: >1700 mg/kg ^[2]	Eye (human): 2	00 ppm irritant
Skin (rabbit):500 mg/24h moderate Skin (rabbit):500 mg/24h moderate Interact (rabbit):1000 ca.15432.6 mg/kg ¹¹ Eye (rabbit):500 mg - SEVERE Intelation (mouse):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Oral (rat):LD50: 3500 mg/kgd ^{2]} Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Oral (rat):LD50: 3500 mg/kgd ^{2]} Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin (rabbit):15 mg/24h mild Inhalation (rat):LC50: 35.5 mg/L24 ^[2] Skin Iritiation(rat):LC50: 35.5 mg/L24 ^[2] Inhalation (rat):LC50: 35.5 mg/L24 ^[2] The material may cause skin iritiation after prolonged or epeated exposure and may produce or ontact skin redness, swelling, the production of vesides	xylene	Inhalation (rat) LC50: 5000 ppm/4h ^[2]	Eye (rabbit): 5 r	mg/24h SEVERE
TOXICTY IRRITATION Demail (rabbil) LGG: ca. 15432.6 mg/kg ^[1] Eye (rabbil): 500 mg · SEVERE Inhalation (nouse) LGG: 35.5 mg/L2H ^[2] Skin (rabbil): 500 mg · SEVERE Inhalation (all LGG: 55.5 mg/L2H ^[2]) Skin (rabbil): 15 mg · SEVERE Inhalation (all LGG: 55.5 mg/L2H ^[2]) Skin (rabbil): 15 mg · SEVERE Inhalation (all LGG: 55.5 mg/L2H ^[2]) Skin (rabbil): 15 mg · SEVERE Inhalation (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) Oral (all LGG: 55.5 mg/L2H ^[2]) The material may cause skin infration after prolonged or opeated exposure and may produce or outcat skin redness, swelling, the production of vesicles scaling and thickening of the skin. TYLENE * Reproductive effector in rats ETHYLBENZENE Lever changes, utheral tract, effects on ferility, footoxichy, specific developmental abnormalities (musculoskeletal system) recorded. XYLENE, ETHYLBENZENE The following information refers to contact alalergens as a group and may not be specific to this product.		Oral (rat) LD50: 4300 mg/kgt ^[2]	Eye (rabbit): 87	' mg mild
Demail (rabbit) LD50: ca.15432.6 mg/kg ¹¹] Eye (rabbit): 500 mg - SEVERE inhalation (mouse) LC50: 35.5 mg/L2H ²¹ Skin (rabbit): 15 mg/24h mild inhalation (mouse) LC50: 35.6 mg/L2H ²¹ Skin (rabbit): 15 mg/24h mild Oral (rat) LD50: 3500 mg/kgd ²¹ Total (rabbit): 15 mg/24h mild I. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's msds. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances TOLUEN The material may cause skin initiation after prolonged or repeated exposure and may produce series, swelling, the production of vesicles scaling and thickening of the skin. BISOCYANATE POLYMER *Bayer SDS ** Ardex SDS RALI GP HARDENEE LVer changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI GP HARDENEE LVer changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities HEXAMETHYLENE The following information refers to contact allergens as a group on unced inflammation. VILENE, ETHYLBENZENE The material may produce severe irritation to the eye causing and may may not be specific to this product. Skin Irritation/Corrosion Carcinogenicity Manuel Carcinogenicity Manuel Carcinogenicity Serious Eye Stot - Single Exposure Stot - Single Exposure			Skin (rabbit):50	0 mg/24h moderate
ethylbenzene Inhalation (indicuse) LC50: 35.5 mg/L2H ^[2] Skin (rabbit): 15 mg/24h mild Inhalation (indicuse) LC50: 35.5 mg/L2H ^[2] Inhalation (indicuse) LC50: 35.5 mg/L2H ^[2] Inhalation (indicuse) LC50: 35.5 mg/L2H ^[2] Oral (rat) LD50: 3500 mg/kgd ^{2]} Inhalation (indicuse) LC50: 55 mg/L2H ^[2] Inhalation (indicuse) LC50: 55 mg/L2H ^[2] Legenet: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's msds. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances TOLUENE The material may cause skin initiation after prolonged or repeated exposure and may produce on tact skin redness, swelling, the production of vesicles exclaing and thickening of the skin. BilsocYANATE POLYMER "Bayer SDS ** Ardex SDS XYLENE Reproductive effector in rats DIISOCYANATE POLYMER Inheratin fract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI OP HARDENER, HEXAMETHYLENE The following information refers to contact allergens as a group and may not be specific to this product. VIENE, ETHYLBENZENE The material may produce severe irritation to the eye causing pronounced inflammation. Stin Initiation/Corrosion Stort - Single Exposure Serious Eye Stort - Single Exposure Stort - Single Exposure Stort - Single		ΤΟΧΙΟΙΤΥ	IRRITATION	
Inhalation (ral) LC50: 55 mg/L2H ^[2] Oral (ral) LD50: 3500 mg/kgd ^{2]} Legenei: 1. Value obtained from Europe ECHA Registered Substances - Acute toxich/2.* Value obtained from manufacturer's msds. Unless otherwise specified dete extracted from RTECS - Register of Toxic Effect of chemical Substances TOLUENE The material may cause skin inflation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesides caling and thickning of the skin. BISOCYANATE FOLYMER *Bayer SDS ** Ardex SDS CTHYLEBENZENE Reproductive effector in rats CHANTE FOLYMER Liver changes, utheral tract, effects on fertility, foototoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI OP HARDENER, HEXAMETHYLENE Liver changes, utheral tract, effects on fertility, foototoxicity, specific developmental abnormalities (musculoskeletal system) recorded. XYLENE, ETHYLBENZENE The material may produce severe iritation to the eye causing pronounced iriflammation. XYLENE, ETHYLBENZENE The material may produce severe iritation to the eye causing pronounced iriflammation. XYLENE, ETHYLBENZENE The material may produce severe iritation to the eye causing pronounced iriflammation. Strine following information refers to contact allergens as a group and may not be specific to this product. Mexametrical severe severe iritation to the eye causing the production of the severe severe severe severe iritation for severe sever		Dermal (rabbit) LD50: ca.15432.6 mg/kg ^[1]	Eye (rabbit): 50	0 mg - SEVERE
Oral (rat) LD50: 3500 mg/kgd ^[2] Legend: 1. Value obtained from Europe ECHA Registered Substances: - Acute toxicity 2.* Value obtained from manufacturer's msds. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances ToLUENC The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesides BEXAMETHYLENE ************************************	ethylbenzene	Inhalation (mouse) LC50: 35.5 mg/L/2H ^[2]	Skin (rabbit): 15	5 mg/24h mild
Legend: 1. Value abtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's msds. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances TOLUENE The material may cause skin iritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles scaling and thickening of the skin. HEXAMETHYLENE * Bayer SDS ** Ardex SDS XYLENE Reproductive effector in rats It is contact allergens as a group and may not be specific to this product. The following information refers to contact allergens as a group and may not be specific to this product. KXLENE, ETHYLBENZENE The material may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE The material may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE The material may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE The material may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE Intervial may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE Intervial may produce severe initiation to the eye causing pronounced inflammation. KXLENE, ETHYLBENZENE Intervial may produce severe initiation to the eye causing to pronounced inflammation.		Inhalation (rat) LC50: 55 mg/L/2H ^[2]		
extracted from RTECS - Register of Toxic Effect of chemical Substances roluent The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles hEXAMETHYLENE DIISOCYANATE POLYMER HEXAMETHYLENE DIISOCYANATE POLYMER HEXAMETHYLENE Cure changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI OF HARDENER HEXAMETHYLENE DIISOCYANATE POLYMER HEXAMETHYLENE DIISOCYANATE		Oral (rat) LD50: 3500 mg/kgd ^[2]		
TOLUENE The material may cause skin irritation after prolonged or repeated exposure and may produce or cact skin redness, swelling, the production of vesicles HEXAMETHYLENE DIISOCYANATE POLYMER * Bayer SDS ** Ardex SDS XYLENE Reproductive effector in rats ETHYLBENZENE Liver changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI OP HARDENER, HEXAMETHYLENE DIISOCYANATE The following information refers to contact allergens as a group and may not be specific to this product. XYLENE, ETHYLBENZENE The material may produce severe irritation to the eye causing pronounced inflammation. XYLENE, ETHYLBENZENE The material may produce severe irritation to the eye causing pronounced inflammation. Serious Eye Diange/Irritation/Corrosion Acute Toxicity Serious Eye Serious Eye Diange/Irritation STOT - Single Exposure Respiratory or Skin Respiratory or Skin Sensitisation Carcinogenicity Stot - Repeated Exposure Stot - Repeated Exposure	Legend:	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's msds. Unless otherwise specified data		
Inducement scaling and thickening of the skin. HEXAMETHYLENE DIISOCYANATE POLYMER * Bayer SDS ** Ardex SDS XYLENE Reproductive effector in rats ETHYLBENZENE DIISOCYANATE POLYMER, HEXAMETHYLENE DIISOCYANATE POLYMER, SCALING PHARDENER, HEXAMETHYLENE DIISOCYANATE POLYMER, HEXAMETHYLENE DIISOCYANATE POLYMER, HEXAMETHYLENE			Guissianous	
DIISOCYANATE POLYMER "Bayer SUS" Ardex SUS XYLENE Reproductive effector in rats ETHYLBENZENE Liver changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded. RALI GP HARDENER, HEXAMETHYLENE The following information refers to contact allergens as a group and may not be specific to this product. VIENE, ETHYLBENZENE The material may produce severe irritation to the eye causis pronounced inflammation. XYLENE, ETHYLBENZENE The material may produce severe irritation to the eye causis pronounced inflammation. KALter Toxicity One material may produce severe irritation to the eye causis pronounced inflammation. Skin Irritation/Corrosion Image: Serious Eye Image: Serious Eye Image: Serious Eye Bespiratory or Skin Image: Serious Eye Stot - Repeated Exposure Image: Serious Eye Respiratory or Skin Image: Serious Eye Stot - Repeated Exposure Image: Serious Eye	TOLUENE		peated exposure and may produce o	n contact skin redness, swelling, the production of vesicles
Image: Constraint of the second of the se		* Bayer SDS ** Ardex SDS		
RALI GP HARDENER, HEXAMETHYLENE DIISOCYANATE POLYMER, HEXAMETHYLENE DIISOCYANATE The following information refers to contact allergens as a group and may not be specific to this product. XYLENE, ETHYLBENZENE The material may produce severe irritation to the eye causing pronounced inflammation. Kuis Irritation/Corrosion Metaolity Serious Eye Damage/Irritation Stort - Single Exposure Respiratory or Skin sensitisation Metaolity Stort - Repeated Exposure	XYLENE	Reproductive effector in rats		
HEXAMETHYLENE DISOCYANATE POLYMER, HEXAMETHYLENE DISOCYANATEThe following information refers to contact allergens as a group and may not be specific to this product.XYLENE, ETHYLBENZENE DISOCYANATEThe material may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEThe material may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEThe material may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing pronounced inflammation.KYLENE, ETHYLBENZENE DISOCYANATEMaterial may produce severe irritation to the eye causing produce severe irritation to the eye causing produce severe irritation to the eye causing produce severe se	ETHYLBENZENE	Liver changes, utheral tract, effects on fertility, foetotoxicity, specific developmental abnormalities (musculoskeletal system) recorded.		
Acute Toxicity Image: Constraint of the second of the se	HEXAMETHYLENE DIISOCYANATE POLYMER, HEXAMETHYLENE	The following information refers to contact allergens as a group and may not be specific to this product.		
Skin Irritation/Corrosion Model Reproductivity Serious Eye Damage/Irritation Model STOT - Single Exposure Respiratory or Skin sensitisation Model STOT - Repeated Exposure	XYLENE, ETHYLBENZENE	The material may produce severe irritation to the eye causing pronounced inflammation.		
Skin Irritation/Corrosion Image: Constraint of the system of the syste	Acute Toxicity	×	Carcinogenicity	×
Serious Eye Damage/Irritation STOT - Single Exposure Respiratory or Skin sensitisation STOT - Repeated Exposure		✓		✓
Respiratory or Skin sensitisation STOT - Repeated Exposure	-	*		*
sensitisation	Respiratory or Skin	¥	STOT - Repeated Exposure	0
Mutagenicity V Aspiration Hazard V		0		
	Mutagenicity	0	Aspiration Hazard	0

Page 8 of 10

RALI GP HARDENER

	седена:	 Data required to make dassification available Data available but does not fill the criteria for classification Data Not Available to make classification 	
CMR STATUS			
REPROTOXIN	toluene	ILO Chemicals in the electronics industry that have toxic effects on reproduction	
REPROTOXIN	xylene	ILO Chemicals in the electronics industry that have toxic effects on reproduction	
SKIN	toluene	New Zealand Workplace Exposure Standards (WES) - Skin	Skin absorption

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

May cause long-term adverse effects in the aquatic environment.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
toluene	LOW (Half-life = 28 days)	LOW (Half-life = 4.33 days)
hexamethylene diisocyanate polymer	HIGH	HIGH
hexamethylene diisocyanate	LOW	LOW
xylene	HIGH (Half-life = 360 days)	LOW (Half-life = 1.83 days)
ethylbenzene	HIGH (Half-life = 228 days)	LOW (Half-life = 3.57 days)

Bioaccumulative potential

Ingredient	Bioaccumulation
toluene	LOW (BCF = 90)
hexamethylene diisocyanate polymer	LOW (LogKOW = 7.5795)
hexamethylene diisocyanate	LOW (LogKOW = 3.1956)
xylene	MEDIUM (BCF = 740)
ethylbenzene	LOW (BCF = 79.43)

Mobility in soil

Ingredient	Mobility
toluene	LOW (KOC = 268)
hexamethylene diisocyanate polymer	LOW (KOC = 18560000)
hexamethylene diisocyanate	LOW (KOC = 5864)
ethylbenzene	LOW (KOC = 517.8)

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods

Product / Packaging disposal		
	Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations 2001.	

SECTION 14 TRANSPORT INFORMATION

Labels Required	
	RANMARLE J
Marine Pollutant	NO
HAZCHEM	•3Y
Land transport (UN)	
UN number	1263
Packing group	
UN proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)
Environmental hazard	No relevant data

Transport hazard class(es)	Class3SubriskNot Applicable
Special precautions for user	Special provisions163;223;367Limited quantity5 L

Air transport (ICAO-IATA / DGR)

UN number	1263	
Packing group	III	
UN proper shipping name	Paint (including paint, lacquer, enamel, stain, shellac, varnish, reducing compounds)	polish, liquid filler and liquid lacquer base); Paint related material (including paint thinning or
Environmental hazard	No relevant data	
Transport hazard class(es)	ICAO/IATA Class3ICAO / IATA SubriskNot ApplicableERG Code3L	
Special precautions for user	Special provisions Cargo Only Packing Instructions Cargo Only Maximum Qty / Pack Passenger and Cargo Packing Instructions Passenger and Cargo Maximum Qty / Pack Passenger and Cargo Limited Quantity Packing Instructions Passenger and Cargo Limited Maximum Qty / Pack	A3 A72 A192 366 220 L 355 60 L Y344 10 L

Sea transport (IMDG-Code / GGVSee)

UN number	1263		
Packing group	III		
UN proper shipping name	PAINT (including paint, lacquer, enamel, stain, shellac, varnish, polish, liquid filler and liquid lacquer base) or PAINT RELATED MATERIAL (including paint thinning or reducing compound)		
Environmental hazard	Not Applicable		
Transport hazard class(es)	IMDG Class3IMDG SubriskNot Applicable		
Special precautions for user	EMS NumberF-E, S-ESpecial provisions163 223 955Limited Quantities5 L		

Transport in bulk according to Annex II of MARPOL 73 / 78 and the IBC code

Source	Ingredient	Pollution Category
IMO MARPOL 73/78 (Annex II) - List of Noxious Liquid Substances Carried in Bulk	toluene	Y
IMO MARPOL 73/78 (Annex II) - List of Noxious Liquid Substances Carried in Bulk	hexamethylene diisocyanate	Y
IMO MARPOL 73/78 (Annex II) - List of Noxious Liquid Substances Carried in Bulk	xylene	Y
IMO MARPOL 73/78 (Annex II) - List of Noxious Liquid Substances Carried in Bulk	ethylbenzene	Y

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

This substance is to be managed using the conditions specified in an applicable Group Standard		
HSR Number	Group Standard	
HSR002669	Surface Coatings and Colourants (Flammable, Toxic [6.7]) Group Standard 2006	

toluene(108-88-3) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs","New Zealand Workplace Exposure Standards (WES)","New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals"
hexamethylene diisocyanate polymer(28182-81-2) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","New Zealand Workplace Exposure Standards (WES)","New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals"
hexamethylene diisocyanate(822-06-0) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","New Zealand Workplace Exposure Standards (WES)","New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals"
xylene(1330-20-7) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs","New Zealand Workplace Exposure Standards (WES)","New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals"
ethylbenzene(100-41-4) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs","New Zealand Workplace Exposure Standards (WES)","New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals"

Location Test Certificate

Subject to Regulation 55 of the Hazardous Substances (Classes 1 to 5 Controls) Regulations a location test certificate is required when quantity greater than or equal to those indicated below are present.

Hazard Class	Quantity beyond which controls apply for closed containers	Quantity beyond which controls apply when use occurring in open containers
3.1C	500 L in containers greater than 5 L 1500 L in containers up to and including 5 L	250 L 250 L

Approved Handler

.

Subject to Regulation 56 of the Hazardous Substances (Classes 1 to 5 Controls) Regulations, the substance must be under the personal control of an Approved Handler when present in a quantity greater than or equal to those indicated below.

Class of substance	Quantities
Not Applicable	Not Applicable
National Inventory	Status
Australia - AICS	Υ
Canada - DSL	Υ
China - IECSC	Υ
Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	Υ
Korea - KECI	Υ
New Zealand - NZIoC	Υ
Philippines - PICCS	Υ
USA - TSCA	Υ
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Ingredients with multiple cas numbers

Name	CAS No
hexamethylene diisocyanate polymer	1192214-73-5, 28182-81-2, 53200-31-0

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at:

.....

www.chemwatch.net/references

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.